Over twenty years of experience in private and public equity investment management and research. Former senior sell-side analyst at Lombard Odier for biotech and medical technology industries; former scientist at the Swiss Federal Institute of Technology. MSc and PhD in chemistry from ETH Zurich and Chartered Financial Analyst since 2002. Board member of Swixx Biopharma, Sphingotec, Numab, Farmalatam and and Board Observer Tata 1mg.